Quest Diagnostics Launches Advanced Pharmacogenomic Test Service for Providers.

Quest Diagnostics has launched a new pharmacogenomic test service to help clinicians understand patients' genetic responses to select drug therapies. The service aims to optimize prescribing across various medical specialties, including psychiatry, neurology, cardiology, oncology, and rheumatology. By utilizing genetic information, providers can determine appropriate medications and dosages for each patient. This offering is designed to address the complexities of drug response and polypharmacy treatment.

September 02, 2025 — Quest Diagnostics (NYSE: DGX) has introduced a new pharmacogenomic (PGx) laboratory test service, designed to assist healthcare providers in understanding patients' genetic responses to select drug therapies. This innovative offering aims to optimize prescribing across various medical specialties, including psychiatry, neurology, cardiology, oncology, and rheumatology. By leveraging genetic insights, providers can determine appropriate medications and dosages for each patient, addressing the complexities of drug response and polypharmacy treatment.

The new PGx service includes 17 genes and 4 HLA alleles, encompassing clinically actionable pharmacogenetic associations informed by expert groups like the Clinical Pharmacogenetics Implementation Consortium (CPIC), the Food and Drug Administration (FDA), and ClinPGx. The service offers a comprehensive report with genotype (diplotye) and predicted phenotypic response, along with vital medication guidance via a link to a personalized report powered by Coriell Life Sciences (now InformedDNA®). Clinicians also have access to GeneDose LIVE, a clinical decision support tool that evaluates each medication for genetic and non-genetic risks in the context of all other prescribed therapies.

Research indicates that PGx testing has the potential to prevent therapeutic failure and adverse drug interactions (ADIs), reducing unnecessary drug costs and the management of drug-related complications [1]. The service is available through Quest Diagnostics' extensive network of patient service centers and offers convenient home collection services for patients facing scheduling, distance, or other barriers to in-office testing.

Quest Diagnostics, in partnership with InformedDNA, aims to harness the power of precision medicine to optimize clinical decisions, improve outcomes, and reduce healthcare costs. The combined expertise of InformedDNA and Coriell Life Sciences ensures that healthcare organizations have access to the highest quality, most current genomics insights, bridging the gap between genetic knowledge and clinical application.

References:
1. Quest Diagnostics (2025). Realizing the Value of Pharmacogenomic Testing: For Patients and Health Systems [White Paper]